May 27, 2013
Novartis Pharma submitted an update of its internal investigation to three medical societies on May 22, acknowledging that a former employee was involved in five investigator-led studies on its best-selling angiotensin receptor blocker Diovan (valsartan), but denied the possibility of...read more